NCT05040789View on ClinicalTrials.gov

Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 22, 2021

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

CoVLP formulation

"The Coronavirus-Like Particle (CoVLP) COVID-19 Vaccine is composed of recombinant spike (S) glycoprotein expressed as virus-like particles (VLPs).~The 3.75 µg dose of CoVLP will be administered with the adjuvant AS03 (manufactured by GlaxoSmithKline)."

Trial Locations (2)

N1H 1B1

Dawson Clinical Research, Guelph

M4G 3E8

LMC Manna Research, Toronto

Sponsors

Lead Sponsor

Medicago
All Listed Sponsors
lead

Medicago

INDUSTRY

NCT05040789 - Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine | Biotech Hunter | Biotech Hunter